



WAP3 Rec'd PCT/PTO 20 MAR 2006

PTO/SB/21 (09-04)

p et

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/540,803
		Filing Date	June 23, 2005
		First Named Inventor	Green, Daniel T.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submission	189	Attorney Docket Number	022354-000310US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (2 pgs)	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard PTO/SB/08A and PTO/SB/08B (3 pgs) References AY-BY (183 pgs)
<input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Randolph Ted Apple		
Date	3/15/2006	Reg. No.	36,429

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Signature			
Typed or printed name	Anthony J. Marshall	Date	3/15/06

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 3/15/06

TOWNSEND and TOWNSEND and CREW LLP

By: 
Anthony J. Marshall

PATENT
Attorney Docket No.: 022354-000310US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniel GREEN et al.

Application No.: 10/540,803

Filed: June 23, 2005

For: COMPOSITIONS AND METHODS
FOR THE PREVENTION AND
CONTROL OF INSULIN-INDUCED
HYPOGLYCEMIA

Examiner: Unassigned

Art Unit: Unassigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of references AY-BY are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or

Daniel GREEN et al.
Application No.: 10/540,803
Page 2

are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Randolph Ted Apple
Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RTA:crf
60675489 v1



Substitute for form 1469A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	10/540,803
Filing Date	June 23, 2005
First Named Inventor	Green, Daniel T.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	022354-000310US

U.S. PATENT DOCUMENTS+


Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,572,542	06-03-2003	Houben et al.	
	AB	US-6,566,490	05-20-2003	Maniquib et al.	
	AC	US-6,520,326	02-18-2003	McIvor et al.	
	AD	US-6,461,331	10-08-2002	Van Antwerp	
	AE	US-6,261,280	07-17-2001	Houben et al.	
	AF	US-6,135,978	10-24-2000	Houben et al.	
	AG	US-6,093,167	07-25-2000	Houben et al.	
	AH	US-5,919,216	07-06-1999	Houben et al.	
	AI	US-5,814,600	09-29-1998	Rink et al.	
	AJ	US-5,741,211	04-21-1998	Renirie et al.	
	AK	US-5,656,590	08-12-1997	Rink et al.	
	AL	US-5,527,771	06-18-1996	Beaumont et al.	
	AM	US-5,508,260	04-16-1996	Beaumont et al.	
	AN	US-5,474,552	12-12-1995	Palti	
	AO	US-5,321,008	06-14-1994	Beaumont et al.	
	AP	US-5,237,993	08-24-1993	Skrabal	
	AQ	US-5,190,041	03-02-1993	Palti	
	AR	US-5,101,814	04-07-1992	Palti	
	AS	US-4,633,878	01-06-1987	Bombardieri	
	AT	US-4,538,616	09-03-1985	Rogoff	
	AU	US-4,003,379	01-18-1977	Ellinwood, Jr.	
	AV	US-2,902,408	09-01-1959	Bouman et al.	
	AW	US-2002/0119146	08-29-2002	Dupre	
	AX	US-2002/0026141	02-28-2002	Houben et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AY	WO	02/43566	A2	06-06-2002			<input type="checkbox"/>
	AZ	GB	748857		05-09-1956			<input type="checkbox"/>
	BA	GB	844434		08-10-1960			<input type="checkbox"/>
	BB	GB	831907		04-06-1960			<input type="checkbox"/>
	BC	GB	766994		01-30-1957			<input type="checkbox"/>
	BD	GB	766995		01-30-1957			<input type="checkbox"/>

Examiner
SignatureDate
Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. 60675489



Substitute for form 1449B PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/540,803
Filing Date	June 23, 2005
First Named Inventor	Green, Daniel T.
Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number 022354-000310US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BE	ABS et al., "Hypoglycemia owing to inappropriate glucagons secretion treated with a continuous subcutaneous glucagons infusion system," <u>Acta Endocrinol (Copenh)</u> , 122(3):319-322 (1990).	<input type="checkbox"/>
	BF	ATVALL et al., "Insulin-antagonistic effects of pulsatile and continuous glucagons infusions in man--a comparison with the effect of adrenaline," <u>J. Clin Endocrinol. Metab.</u> , 74(5):1110-1115 (1992).	<input type="checkbox"/>
	BG	AYNSLEY-GREEN et al., "Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia," <u>Arch. Dis. Child.</u> , 56(7):496-508 (1981).	<input type="checkbox"/>
	BH	BERGMAN et al., "Central role of the adipocyte in the metabolic syndrome," <u>J. Investig. Med.</u> , 49(1):119-126 (2001).	<input type="checkbox"/>
	BI	BOLLI et al., "Nocturnal blood glucose control in type I diabetes mellitus," <u>Diabetes Care</u> , 16(suppl. 3):71-89 (1993).	<input type="checkbox"/>
	BJ	BRATUSCH-MARRIAN et al., "The role of 'diabetogenic' hormones on carbohydrate and lipid metabolism following oral glucose loading in insulin dependent diabetics: effect of acute hormone administration," <u>Diabetologia</u> , 21(4):387-393 (1981).	<input type="checkbox"/>
	BK	BRAY, G.A., "The Zucker-fatty rat: a review," <u>Fed. Proc.</u> , 36(2):148-153 (1977).	<input type="checkbox"/>
	BL	BREMER et al., "Protein delivery with infusion pumps," <u>Pharm. Biotechnol.</u> , 10:239-254 (1997).	<input type="checkbox"/>
	BM	CEDERBLAD et al., "Effect of glucagons on glucose production, lipolysis, and gluconeogenesis in familial hyperinsulinism," <u>Horm. Res.</u> , 50(2):94-98 (1998).	<input type="checkbox"/>
	BN	CHRISTIANSEN et al., "Zinc-protamine-glucagon in the treatment of Paget's disease of bone. Preliminary Report," <u>Acta Med. Scand.</u> , 196(6):495-496 (1974).	<input type="checkbox"/>
	BO	CLARKE et al., "The effect of hyperglucagonemia on blood glucose concentrations and on insulin requirements in insulin-requiring diabetes mellitus," <u>Diabetes</u> , 27(6):649-652 (1978).	<input type="checkbox"/>
	BP	CRYER et al., "Hypoglycemia in Diabetes," <u>Diabetes Care</u> , 26(6):1902-1912 (2003).	<input type="checkbox"/>
	BQ	DAY et al., "Depot-glucagon in the treatment of McArdle's disease," <u>Aust N.Z. J. Med.</u> , 15(6):748-750 (1985).	<input type="checkbox"/>
	BR	HAYMOND et al., "Mini-Dose Glucagon Rescue for Hypoglycemia in children With Type 1 Diabetes," <u>Diabetes Care</u> , 24(4):643-645 (2001).	<input type="checkbox"/>
	BS	IVKOVIC-LAZAR, T., "Development and differentiation of adipose tissue," <u>Med. Pregl.</u> , 56(3-4):142-145 (2003), abstract, article in Croatian.	<input checked="" type="checkbox"/>
	BT	KALIMA et al., "The effect of zinc-protamine-glucagon in acute pancreatitis," <u>Ann. Chir. Gynaecol.</u> , 69(6):293-295 (1980).	<input type="checkbox"/>

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/540,803
Filing Date	June 23, 2005
First Named Inventor	Green, Daniel T.
Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number 022354-000310US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BU	KOLLEE et al., "Persistent neonatal hypoglycaemia due to glucagons deficiency," <u>Arch Dis Child</u> , 53(5):422-424 (1978).	<input type="checkbox"/>
	BV	NICOLAIDIS, S., "Physiology of food intake and regulation of body weight," <u>Ann. Endocrinol.</u> , 49(2):89-97 (1988) abstract, article in French..	<input type="checkbox"/>
	BW	PICHLER et al., "Haemodynamic effects of depot zinc protamine glucagons in heart failure," <u>Wein Klin Wochenschr.</u> , 91(2):49-51 (1979) abstract only, article in German.	<input type="checkbox"/>
	BX	SCHMID et al., "McArdle's disease: therapeutic use of depot-glucagon," <u>Dtsch Med. Wochenschr.</u> , 107(47):1809-1811 (1982) abstract only, article in German.	<input type="checkbox"/>
	BY	TRADING et al., "Bioogical and Chemical Properties of Two Glucagon Preparations with Prolonged Action," <u>Eur. J. Pharmacology</u> , 7:206-210 (1969).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.